You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Baxter
Express Scripts
Medtronic
Merck

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,648,077


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,648,077 protect, and when does it expire?

Patent 8,648,077 protects CAPLYTA and is included in one NDA.

This patent has twenty-two patent family members in sixteen countries.

Summary for Patent: 8,648,077
Title:4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrro- lo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
Abstract: The present invention relates to toluenesulfonic acid addition salt crystals of 4-((6bR,10aS)-3-Methyl-2,3,6b,9,10,10a-Hexahydro-1H-Pyrido[3',4':4,5]Pyrr- olo[1,2,3-De]Quinoxalin-8(7H)-yl)-1-(4-Fluorophenyl)-1-Butanone, the method of making and using such crystals.
Inventor(s): Tomesch; John (New York, NY), Wennogle; Lawrence P. (New York, NY)
Assignee: Intra-Cellular Therapies, Inc. (New York, NY)
Application Number:12/922,056
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,648,077
Patent Claim Types:
see list of patent claims
Composition; Compound; Process;

Recent additions to Drugs Protected by US Patent 8,648,077

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Intra-cellular CAPLYTA lumateperone tosylate CAPSULE 209500 Dec 20, 2019 RX Yes   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 8,648,077

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Intra-cellular CAPLYTA lumateperone tosylate CAPSULE;ORAL 209500-001 Dec 20, 2019 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,648,077

PCT Information
PCT FiledMarch 12, 2009PCT Application Number:PCT/US2009/001608
PCT Publication Date:September 17, 2009PCT Publication Number: WO2009/114181

International Family Members for US Patent 8,648,077

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009223701   Start Trial
Canada 2716730   Start Trial
China 102046175   Start Trial
China 105237536   Start Trial
Denmark 2262505   Start Trial
European Patent Office 2262505   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
McKesson
Mallinckrodt
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.